Neurofibromatosis type 1 (NF1), a common inherited disorder, causes skin-pigmentation and CNS abnormalities, and increases the risk of developing several types of cancer. It varies widely in clinical presentation, even in family members carrying an identical mutation at the NF1 locus, suggesting genetic or environmental modifiers. To probe underlying mechanisms, Shin, Padmanabhan et al. studied the zebrafish homologues of human NF1 – nf1a and nf1b – and used targeted approaches to create nf1-null zebrafish, which showed melanophore defects and a range of CNS abnormalities at the larval stage. As hypothesised for human NF1, zebrafish nf1 genes also act as tumour suppressors: nf1-null larvae showed hyperactivation of Ras in the spinal cord, and combined loss of nf1 and p53 accelerated tumorigenesis. These data indicate that zebrafish nf1a and nf1b are tumour suppressors with crucial roles in CNS development. This is also the first animal model of NF1 in which pigmentation defects – an important feature of the human disease – have been documented. Page 881
Zebrafish model of neurofibromatosis type 1 Open Access
- Split-screen
- Views Icon Views Open Menu
- Open the PDF for in another window
-
Article Versions Icon
Versions
- Version of Record 01 November 2012
- Share Icon Share
-
Tools Icon
Tools
Open Menu
- Search Site
Zebrafish model of neurofibromatosis type 1. Dis Model Mech 1 November 2012; 5 (6): 707. doi:
Download citation file:
Advertisement
Cited by
Interviews with Biologists @ 100 conference speakers

Explore our interviews with keynote speakers from the Biologists @ 100 conference, hosted to celebrate our publisher’s 100th anniversary, where we discuss climate change and biodiversity with Hans-Otto Pörtner and Jane Francis, health and disease with Charles Swanton and Sadaf Farooqi, and emerging technologies with Manu Prakash and Jennifer Lippincott-Schwartz.
A new perspective on disease research
DMM publishes perspectives – peer-reviewed articles that provide expert analysis of a topic important to the disease research community. Read our collection from authors presenting new or potentially controversial ideas or hypotheses, to help address future challenges and forge new directions.
Read & Publish Open Access publishing: what authors say

We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
Fast & Fair peer review

Our sister journal Biology Open has recently launched the next phase of their Fast & Fair peer review initiative: offering high-quality peer review within 7 working days. To learn more about BiO’s progress and future plans, read the Editorial by Daniel Gorelick, or visit the Fast & Fair peer review page.
History of our journals

As our publisher, The Company of Biologists, turns 100 years old, read about DMM’s history and explore the journey of each of our sister journals: Development, Journal of Cell Science, Journal of Experimental Biology and Biology Open.
Other journals from
The Company of Biologists